Search results
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition
Investing.com· 3 days agoThe earnings call also marked a significant leadership transition, with CEO Rick Gonzalez announcing...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Cut by Russell Investments Group Ltd.
ETF DAILY NEWS· 18 hours agoRussell Investments Group Ltd. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 84.5% during the fourth quarter, according to its most recent Form 13F filing with ...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class PRAME-targeted...
Newswise· 2 days agoMD Anderson and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) appli
Kura Oncology, Inc. (NASDAQ:KURA) Stock Holdings Lessened by Mirae Asset Global Investments Co. Ltd.
ETF DAILY NEWS· 6 days agoMirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 5.7% in the fourth quarter, according to the company in its most ...
Cullinan Oncology, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest
ETF DAILY NEWS· 3 days agoCullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 1,680,000 shares ...
Vor Biopharma’s (VOR) “Outperform” Rating Reiterated at Wedbush
ETF DAILY NEWS· 6 days agoWedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report released on Tuesday, Benzinga reports. Wedbush currently has a $11.00 price ...
How Big Pharma Is Taking A Page Out Of Novartis' Playbook
Investor's Business Daily· 7 days agoNovartis (NVS) blazed a trail for treating cancer with targeted radiopharmaceuticals, a treatment that sends radiation directly to cancer cells. Novartis' prostate cancer drug, Pluvicto, which ...